Skip to main content
Kathryn Mileham, MD, Oncology, Charlotte, NC, Atrium Health's Carolinas Medical Center

KathrynFMilehamMDFACP

Oncology Charlotte, NC

Chief, Section of Thoracic Medical Oncology; Levine Cancer Institute/Carolinas HealthCare System

Dr. Mileham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mileham's full profile

Already have an account?

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 2003 - 2006
  • Medical University of South Carolina
    Medical University of South CarolinaClass of 2003

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2009 - 2025
  • TN State Medical License
    TN State Medical License 2006 - 2010

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Effectiveness of ASCO’s adverse event reporting decision aid: Results from an interventional study. 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Moving Away (Finally) from Doublet Therapy in Lung Cancer: Immunotherapy and KEYNOTE-189September 2018

Press Mentions

  • COVID-19 Mortality Risk Higher Among Older Patients with B-cell Malignancies
    COVID-19 Mortality Risk Higher Among Older Patients with B-cell MalignanciesJanuary 6th, 2022
  • GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer
    GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung CancerDecember 21st, 2021
  • Targeted Therapy for Mutation-Driven Metastatic Non–Small-Cell Lung Cancer: Considerations for ALK-Rearranged Tumors
    Targeted Therapy for Mutation-Driven Metastatic Non–Small-Cell Lung Cancer: Considerations for ALK-Rearranged TumorsApril 15th, 2019

Hospital Affiliations